Status:
UNKNOWN
Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention
Lead Sponsor:
Assiut University
Conditions:
In-stent Restenosis
Eligibility:
All Genders
18-75 years
Brief Summary
To study the relation between ISR and neutrophil-to-lymphocyte ratio (NLR), novel biomarkers (high-sensitivity CRP (hs-CRP), bone morphogenetic protein-2 (BMP-2) and other risk factors (age, sex, smok...
Detailed Description
Coronary artery disease (CAD) is the most common cardiovascular disease and remains a major global public health problem \[1\]. Due to the benefits of a shorter procedure time and reduced invasiveness...
Eligibility Criteria
Inclusion
- Patients with previously implanted 3rd generation DES (Sirolimus, Biolimus, Everolimus, Zotarolimus), whatever the duration since implantation or the setting of implantation or the number of implanted stents, and who are presenting to our institute along the coming two years for CA±PCI because of recurrent chest pain with suspicious of ISR or other newly developed lesions.
Exclusion
- • Previous CABG
- ACS within the last 2ms before the index CA for those undergoing assessment of hs-CRP \& BMP-2
- Heart failure with reduced EF\<40%
- Severe liver or kidney disease
- Autoimmune, inflammatory, or malignant diseases
- Non-available previous PCI CD \& report
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06148441
Start Date
January 1 2024
End Date
February 1 2025
Last Update
November 28 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.